Abstract
The main obstacle to improve the clinical outcome of most of the therapeutic modalities discussed in the previous chapter is therapy resistance, either intrinsic or acquired after treatment. In this chapter we present the major mechanisms underlaying therapy resistance and classify them according to their mode of action in relation to the therapeutic target into mechanisms upstream of the molecular target, at the level of the molecular target downstream of it.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aghi M, Hochberg F, Breakefield XO (2000) Prodrug activation enzymes in cancer gene therapy. J Gene Med 2:148–164. https://doi.org/10.1002/(SICI)1521-2254(200005/06)2:3%3c148:AID-JGM105%3e3.0.CO;2-Q
Borst P, Evers R, Kool M, Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347–357
Dean M, Hamon Y, Chimini G (2001) The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42:1007–1017
Ferreira BI, Lie MK, Engelsen AST, Machado S, Link W, Lorens JB (2017) Adaptive mechanisms of resistance to anti-neoplastic agents. Medchemcomm 8:53–66. https://doi.org/10.1039/c6md00394j
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627. https://doi.org/10.1146/annurev.med.53.082901.103929
Groenendijk FH, Bernards R (2014) Drug resistance to targeted therapies: Deja vu all over again. Mol Oncol 8:1067–1083. https://doi.org/10.1016/j.molonc.2014.05.004
Henriques V, Martins T, Link W, Ferreira BI (2018) The emerging therapeutic landscape of advanced melanoma. Curr Pharm Des 24:549–558. https://doi.org/10.2174/1381612824666180125093357
Hill R et al (2017) TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nat Commun 8:14687. https://doi.org/10.1038/ncomms14687
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726. https://doi.org/10.1038/nrc3599
Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198–210. https://doi.org/10.1016/j.gendis.2016.04.007
Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275–292. https://doi.org/10.1002/path.1706
Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287–294. https://doi.org/10.1038/nature10760
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196:395–406. https://doi.org/10.1083/jcb.201102147
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream Cell 129:1261–1274. https://doi.org/10.1016/j.cell.2007.06.009
O’Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242–2249. https://doi.org/10.1182/blood-2007-03-066936
Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101:161–166. https://doi.org/10.1111/j.1349-7006.2009.01358.x
Paraiso KH et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750–2760. https://doi.org/10.1158/0008-5472.CAN-10-2954
Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349–366. https://doi.org/10.2165/00003088-200544040-00002
Straussman R et al (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500–504. https://doi.org/10.1038/nature11183
Sun C et al (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508:118–122. https://doi.org/10.1038/nature13121
Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369–7375. https://doi.org/10.1038/sj.onc.1206940
Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454. https://doi.org/10.1093/jnci/djm135
Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13:e178–e185. https://doi.org/10.1016/S1470-2045(11)70335-7
van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G (2007) Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs–from bench to bedside. Nat Clin Pract Rheumatol 3:26–34. https://doi.org/10.1038/ncprheum0380
Further Reading
Groenendijk FH, Bernards R (2014) Drug resistance to targeted therapies: Deja vu all over again. Mol Oncol 8:1067–1083. https://doi.org/10.1016/j.molonc.2014.05.004
Holland-Frei cancer medicine, 9th. edn. Wiley-Blackwell (2017) ISBN: 978-1-118-93469-2
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726. https://doi.org/10.1038/nrc3599
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611–629
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Link, W. (2019). Cancer Drug Resistance. In: Principles of Cancer Treatment and Anticancer Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-030-18722-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-18722-4_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-18721-7
Online ISBN: 978-3-030-18722-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)